FDA Inspection 1112951 — Kimberly A. Chapman, M.D., PhD
The FDA completed an inspection of Kimberly A. Chapman, M.D., PhD on November 21, 2019 in Washington, DC. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- November 21, 2019
- Fiscal Year
- 2020
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Washington, DC (United States)
Additional Details
Clinical Investigator (CI)